Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Redwire Corporation and its executives [1] Financial Performance - Redwire reported Q1 2025 revenue of $61.4 million, missing consensus estimates by $13.14 million, which represents a 30.1% year-over-year decline [2] - The company attributed the revenue decline to delays in U.S. government contract awards due to leadership transitions at agencies like NASA and the Space Development Agency, as well as shifting budget priorities under the Trump administration [2] Stock Market Reaction - Following the financial results announcement, Redwire's stock price fell by $0.75 per share, or 6.63%, closing at $10.56 per share on May 12, 2025 [3]

Core Viewpoint - Luminar Technologies, Inc. is under investigation for potential securities fraud and unlawful business practices following the resignation of its founder and CEO, Austin Russell, which led to a significant drop in stock price [1][2]. Group 1: Company Developments - On May 14, 2025, Luminar announced the resignation of founder Austin Russell as President and CEO, effective immediately, due to an inquiry by the Audit Committee regarding the Code of Business Conduct and Ethics [2]. - Following the announcement of Russell's resignation, Luminar's stock price decreased by $0.80 per share, representing a decline of 16.81%, closing at $3.96 per share on May 15, 2025 [2]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Luminar investors regarding possible securities fraud or other unlawful business practices by the company and its officers and/or directors [1].

Core Viewpoint - Metallus Inc. is under investigation for potential securities fraud and unlawful business practices, following a disappointing financial report that led to a significant drop in stock price [1][2]. Financial Performance - Metallus reported non-GAAP earnings per share of $0.07 for Q1 2025, which was $0.05 below consensus estimates [2]. - The company's stock price fell by $1.48, or 11.31%, closing at $11.61 per share on May 9, 2025, after the earnings announcement [2]. Company Background - Pomerantz LLP is a prominent law firm specializing in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors [1] Financial Performance - On May 8, 2025, Globus reported Q1 2025 financial results, with non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06 [2] - Revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [2] - The decline in performance was attributed to softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders [2] Market Reaction - Following the financial results announcement, Globus's stock price dropped by $16.64 per share, or 22.96%, closing at $55.82 per share on May 9, 2025 [2]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Everus Construction Group, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who acquired Everus Construction common stock during the Class Period or through the spinoff from MDU Resources may be eligible for compensation without any out-of-pocket fees [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 3, 2025 [3]. - The lawsuit alleges that Everus Construction made false or misleading statements regarding its business operations, which led to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, highlighting the firm's expertise in this area [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Solaris Energy Infrastructure, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on May 27, 2025 [1]. Group 1: Class Action Details - Investors who purchased Solaris Energy securities between July 9, 2024, and March 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lead plaintiff must file a motion with the Court by May 27, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that Solaris Energy made false and misleading statements regarding Mobile Energy Rentals LLC (MER), including its lack of corporate history in mobile turbine leasing and its non-diversified earnings stream [5]. - It is claimed that MER's co-owner has a criminal background associated with turbine-related fraud, which was not disclosed, leading to an overstatement of the commercial prospects from the MER acquisition [5]. - The lawsuit also asserts that Solaris Energy inflated profitability metrics by failing to properly depreciate its turbines, resulting in materially misleading statements about its business and operations [5].

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BigBear.ai Holdings, Inc. (NYSE: BBAI) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in BigBear.ai, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bigbearai-holdings-inc. Investors have until June 10, 2025, to ask the Court to be a ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Fulgent Genetics, Inc. and its officers or directors [1]. Group 1: Investigation Details - The investigation is initiated on behalf of investors of Fulgent Genetics, Inc. [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Recent Developments - On February 28, 2025, Fulgent disclosed a civil investigative demand from the U.S. Department of Justice concerning potential false claims under the Uninsured Program [3]. - Following this disclosure, Fulgent's stock price decreased by $0.41 per share, representing a 2.61% decline, closing at $15.28 per share on March 3, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Biohaven Ltd. and its officers or directors [1] Group 1: Company Developments - On May 14, 2025, Biohaven announced that the FDA extended the PDUFA date for its new drug application for the treatment of spinocerebellar ataxia by three months to allow for a full review of recent submissions [3] - Following the FDA announcement, Biohaven's stock price dropped by $3.84 per share, or 19.53%, closing at $15.82 per share on May 15, 2025 [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Biohaven to investigate claims related to potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [4]

NEW YORK, May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ibotta, Inc. (NYSE: IBTA).Shareholders who purchased shares of IBTA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/ibotta-loss-submission-form/?id=149530&from=4CLASS PERIOD: This lawsuit is on behalf of persons ...